Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007149627 | Skin | AK | cellular response to external stimulus | 63/1910 | 320/18723 | 2.30e-07 | 9.13e-06 | 63 |
GO:003238619 | Skin | AK | regulation of intracellular transport | 65/1910 | 337/18723 | 3.23e-07 | 1.27e-05 | 65 |
GO:000756826 | Skin | AK | aging | 63/1910 | 339/18723 | 1.83e-06 | 5.42e-05 | 63 |
GO:003519610 | Skin | AK | production of miRNAs involved in gene silencing by miRNA | 18/1910 | 52/18723 | 1.88e-06 | 5.54e-05 | 18 |
GO:005140319 | Skin | AK | stress-activated MAPK cascade | 48/1910 | 239/18723 | 3.43e-06 | 8.82e-05 | 48 |
GO:006096415 | Skin | AK | regulation of gene silencing by miRNA | 17/1910 | 49/18723 | 3.49e-06 | 8.86e-05 | 17 |
GO:00310509 | Skin | AK | dsRNA processing | 18/1910 | 54/18723 | 3.50e-06 | 8.86e-05 | 18 |
GO:00709189 | Skin | AK | production of small RNA involved in gene silencing by RNA | 18/1910 | 54/18723 | 3.50e-06 | 8.86e-05 | 18 |
GO:003287218 | Skin | AK | regulation of stress-activated MAPK cascade | 41/1910 | 192/18723 | 3.57e-06 | 8.96e-05 | 41 |
GO:007030218 | Skin | AK | regulation of stress-activated protein kinase signaling cascade | 41/1910 | 195/18723 | 5.36e-06 | 1.24e-04 | 41 |
GO:001820910 | Skin | AK | peptidyl-serine modification | 61/1910 | 338/18723 | 7.00e-06 | 1.55e-04 | 61 |
GO:006014710 | Skin | AK | regulation of posttranscriptional gene silencing | 17/1910 | 52/18723 | 8.76e-06 | 1.89e-04 | 17 |
GO:003109819 | Skin | AK | stress-activated protein kinase signaling cascade | 48/1910 | 247/18723 | 8.76e-06 | 1.89e-04 | 48 |
GO:00609668 | Skin | AK | regulation of gene silencing by RNA | 17/1910 | 53/18723 | 1.17e-05 | 2.42e-04 | 17 |
GO:001648215 | Skin | AK | cytosolic transport | 36/1910 | 168/18723 | 1.26e-05 | 2.56e-04 | 36 |
GO:001810516 | Skin | AK | peptidyl-serine phosphorylation | 57/1910 | 315/18723 | 1.27e-05 | 2.57e-04 | 57 |
GO:007099728 | Skin | AK | neuron death | 63/1910 | 361/18723 | 1.50e-05 | 2.94e-04 | 63 |
GO:20006378 | Skin | AK | positive regulation of gene silencing by miRNA | 12/1910 | 30/18723 | 1.83e-05 | 3.47e-04 | 12 |
GO:190121425 | Skin | AK | regulation of neuron death | 57/1910 | 319/18723 | 1.87e-05 | 3.52e-04 | 57 |
GO:006053710 | Skin | AK | muscle tissue development | 68/1910 | 403/18723 | 2.18e-05 | 4.03e-04 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP2 | SNV | Missense_Mutation | | c.5158G>A | p.Gly1720Ser | p.G1720S | P11137 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAP2 | SNV | Missense_Mutation | novel | c.5438N>G | p.Thr1813Ser | p.T1813S | P11137 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAP2 | SNV | Missense_Mutation | | c.1633N>C | p.Asp545His | p.D545H | P11137 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.771) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
MAP2 | SNV | Missense_Mutation | rs780652765 | c.4724G>A | p.Arg1575Gln | p.R1575Q | P11137 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A7-A426-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
MAP2 | SNV | Missense_Mutation | | c.2813A>G | p.His938Arg | p.H938R | P11137 | protein_coding | tolerated_low_confidence(0.89) | benign(0.038) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP2 | SNV | Missense_Mutation | | c.2342N>T | p.Gln781Leu | p.Q781L | P11137 | protein_coding | deleterious(0) | benign(0.129) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
MAP2 | SNV | Missense_Mutation | novel | c.2427N>T | p.Met809Ile | p.M809I | P11137 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAP2 | SNV | Missense_Mutation | novel | c.4259N>T | p.Ser1420Leu | p.S1420L | P11137 | protein_coding | deleterious(0) | benign(0.015) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
MAP2 | SNV | Missense_Mutation | | c.1849N>A | p.Asp617Asn | p.D617N | P11137 | protein_coding | deleterious_low_confidence(0.01) | benign(0.31) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP2 | SNV | Missense_Mutation | novel | c.343N>G | p.Gln115Glu | p.Q115E | P11137 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.977) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |